Influence of Different Gonadotropin-releasing Hormone Agonist Administration Methods on Pregnancy Outcomes of Patients Undergoing In-vitro Fertilization-embryo Transfer

Abstract

This study aimed to investigate the effect of different gonadotropin-releasing hormone agonist (GnRH-a) administration methods on pregnancy outcomes of patients undergoing in-vitro fertilization-embryo transfer (IVF-ET). Clinical data of 5217 patients who underwent IVF-ET were retrospectively analyzed. Patients were divided into the long-acting GnRH-a group (n=1330) and the short-acting GnRH-a group (n=3887) based on their various treatment plans. The clinical and laboratory embryo data and clinical pregnancy outcomes were compared between the two groups. The results showed that there were no significant differences in the age, infertility, primary/secondary infertility rate, IVF rate, body mass index (BMI), antral follicle counting (AFC), follicle-stimulating hormone (FSH) level, and the number of transplanted embryos between the two groups (P>0.05). There were no significant differences in the oocyte numbers, MII rate, fertilization rate, cleavage rate and blastocyst formation rate (P>0.05) between the two groups. The gonadotropin (Gn) using days, Gn dose and endometrial thickness were significantly greater in the long-acting GnRH-a group than those in the short-acting GnRH-a group (P<0.01). Additionally, the estradiol (E2) levels, blastocyst freezing rate, embryo utilization rate, transplant cancellation rate and abortion rate were significantly lower in the long-acting GnRH-a group than those in the short-acting GnRH-a group (P<0.01). The clinical pregnancy rate and embryo implantation rate were significantly higher in the long-acting GnRH-a group than in the short-acting GnRH-a group (P<0.01). It was concluded that use of long-acting GnRH-a can effectively reduce the transplant cancellation rate and improve the clinical pregnancy rate of the fresh cycle.

Keywords

gonadotropin-releasing hormone agonist / long-acting / short-acting / in-vitro fertilization-embryo transfer / clinical pregnancy rate

References

[1] GuoN, HuaX, LiYF, et al.. Role of ICSI in Nonmale Factor Cycles as the Number of Oocytes Retrieved Decreases from Four to One. Curr Med Sci, 2018, 38(1): 131-136

[2] WarnerB, WorgulTJ, DragoJ, et al.. Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer. J Clin Invest, 1983, 71(6): 1842-1853

[3] HupeMC, HammererP, KetzM, et al.. Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient Outcomes. Front Oncol, 2018, 8: 543

[4] OliveiraJB, BaruffiR, PetersenCG, et al.. Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis. Reprod Biol Endocrinol, 2010, 8: 107

[5] Al-InanyHG, YoussefMA, AyelekeRO, et al.. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev, 2016, 4: CD001750

[6] RenJ, ShaA, HanD, et al.. Does prolonged pituitary down-regulation with gonadotropin-releasing long- and short-acting GnRH-a hormone agonist improve the live-birth rate in in vitro fertilization treatment?. Fertil Steril, 2014, 102: 75-81

[7] DevrekerF, GovaertsI, BertrandE, et al.. The long-acting gonadotropin-releasing hormone analogues impaired the implantation rate. Fertil Steril, 1996, 65(1): 122-126

[8] AlbuquerqueLE, TsoLO, SaconatoH, et al.. Depot versus daily administration of gonadotrophin-releasing hormone agonistprotocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database Syst Rev, 2013CD002808

[9] WangR, WangF, YangL, et al.. Effects of long-acting GnRH: a prolonged protocol in assisted pregnancy via IVF-ET in infertile patients with PCOS. Minerva Chir, 2018, 73(2): 251-253

[10] SurreyES, SilverbergKM, SurreyMW, et al.. Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis. Fertil Steril, 2002, 78: 699-704

[11] ZhangHJ, SongXR, LüR. Modified super-long down-regulation protocol improves fertilization and pregnancy in patients with poor ovarian responses. Chin Med J (Engl), 2012, 125(16): 2837-2840

[12] GuoYH, LuN, ZhangY, et al.. Comparative study on the pregnancy outcomes of in vitro fertilization-embryo transfer between long-acting gonadotropin-releasing hormone agonist combined with transvaginal ultrasound-guided cyst aspiration and long-acting gonadotropin-releasing hormone agonist alone. Contemp Clin Trials, 2012, 33(6): 1206-1210

[13] DuanL, BaoS, LiK, et al.. Comparing the long-acting and short-acting forms of gonadotropin-releasing hormone agonists in the long protocol of IVF/ICSI Cycles: A retrospective study. J Obstet Gynaecol Res, 2017, 43(6): 1037-1042

[14] GaoJ, XuYW, MiaoBY. Self-control study on reduced-dose depot versus daily administration of gonadotrophin-releasing hormone agonists for pituitary desensitization in in vitro fertilization cycles. J Obstet Gynaecol Res, 2014, 40(7): 1901-1906

[15] YounesG, TulandiT. Effects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis. Fertil Steril, 2017, 108(3): 483-490

[16] LongQQ, ZhangSF, HanY, et al.. Clinical efficacy and safety of gonadotropin releasing hormone agonist combined with estrogen-dydrogesteronea in treatment of endometriosis. Zhonghua Fu Chan Ke Za Zhi (Chinese), 2010, 45(4): 247-251